• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Indonesia·Consumer Cyclical·MRAT.JK
Share

PT Mustika Ratu Tbk Stocks

IDR 440Last Updated 24.07.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

IDR 11.40M

IDR 440
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Based in Indonesia, PT Mustika Ratu Tbk, along with its group of companies, is engaged in manufacturing, marketing, and distributing a diverse range of products. These include herbal and traditional beauty items, personal care essentials, jamu (Indonesian traditional herbal medicine), health beverages, and convenient ready-to-drink options. Their extensive product line features examples such as Herbamuno+ herbal supplements, facial cleansers, hydrating creams, body serums designed for toning, dual-purpose cleansers and toners, as well as various face mask preparations like creams and powders. Established in 1978, the firm maintains its main office in Jakarta, Indonesia, and functions as a subsidiary of PT Mustika Ratu Investama.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITDA, rea

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

26.07.2026 21:33

Revolut Valued at $115 Billion and a Record-Breaking Deal in Asia: Key Takeaways on IPOs as of July 26

26.07.2026 15:01

AI Tools to Combat Cognitive Biases: How Investors Can Use Them

25.07.2026 16:01

Small caps last week: New Nasdaq rules, AI hurting Tripadvisor, Archer's rotorcraft

25.07.2026 13:50

Chevron Discussed with the U.S. How to Protect Its Interests in Kazakhstan from the Effects of the War — WSJ

25.07.2026 13:01

The "Three Seas" Risk Zone, Tesla Hit by Expenses, and "Odyssey" — the Driving Force Behind Movie Theaters

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026